Skip to content

Periodontal Therapy and Genitourinary Inflammation in Patients With Prostatitis and Recurrent Urinary Tract Infections

Impact of Non-surgical Periodontal Therapy on Prostate-specific Antigen Levels and Urinary Tract Infection Recurrence: a Randomized Controlled Clinical Trial

Status
Completed
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07438184
Acronym
PERIO-PSA
Enrollment
60
Registered
2026-02-27
Start date
2024-01-01
Completion date
2025-04-01
Last updated
2026-03-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Periodontitis, Chronic Prostatitis (CP), Urinary Tract Infections

Brief summary

This randomized controlled clinical trial evaluates the impact of non-surgical periodontal therapy on systemic inflammatory markers in patients with chronic prostatitis or recurrent urinary tract infections. Emerging evidence suggests a possible association between periodontal inflammation and genitourinary conditions. A total of 60 male participants diagnosed with periodontitis and either chronic prostatitis or recurrent urinary tract infections were randomly assigned to one of three groups: non-surgical periodontal therapy, oral hygiene instruction only, or no periodontal treatment. The primary outcomes were changes in serum prostate-specific antigen (PSA) levels and the frequency of positive urine cultures over a 120-day follow-up period. The study aims to investigate whether periodontal treatment may reduce systemic inflammatory burden and improve genitourinary clinical parameters.

Detailed description

This parallel-group randomized clinical trial was conducted at a university healthcare center. Eligible participants were adult male patients diagnosed with periodontitis and chronic prostatitis (NIH category III) or recurrent urinary tract infections. Participants were randomly allocated to receive full-mouth scaling and root planing combined with oral hygiene instruction, oral hygiene instruction alone, or no periodontal intervention during the study period. Clinical periodontal parameters, serum PSA levels, and microbiological urine cultures were assessed at baseline and at 120 days. Statistical analyses were performed to evaluate intergroup differences and longitudinal changes.

Interventions

PROCEDURENon-surgical periodontal therapy

Full-mouth scaling and root planing performed under local anesthesia using ultrasonic and hand instruments, completed within two sessions over a one-week period. Participants also received standardized oral hygiene instructions including tooth brushing technique and interdental cleaning guidance.

Standardized oral hygiene instructions including tooth brushing technique, use of interdental cleaning devices, and reinforcement of plaque control measures, without mechanical periodontal instrumentation.

Sponsors

University of Salamanca
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Masking description

Due to the nature of the intervention, blinding of participants and care providers was not feasible.

Intervention model description

Participants were randomly assigned in a parallel design to one of three groups: non-surgical periodontal therapy, oral hygiene instruction, or no periodontal treatment, with a 120-day follow-up period.

Eligibility

Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

* Male participants aged 18 years or older * Diagnosis of chronic prostatitis (NIH category III) or recurrent urinary tract infections * Diagnosis of periodontitis according to the 2017 World Workshop classification * Ability to provide written informed consent

Exclusion criteria

* Antibiotic therapy within the previous 3 months * Systemic immunosuppressive disorders * History of prostate cancer * Ongoing periodontal treatment Severe systemic diseases affecting inflammatory status

Design outcomes

Primary

MeasureTime frameDescription
Change in serum prostate-specific antigen (PSA) levelsBaseline to 120 daysDifference in serum prostate-specific antigen (PSA) levels measured in ng/mL between baseline and 120 days after intervention.

Secondary

MeasureTime frameDescription
Change in frequency of positive urine culturesBaseline to 120 daysDifference in the number of microbiologically confirmed urinary tract infections between baseline and 120 days.

Countries

Spain

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 14, 2026